Want to see OABI full AI Analyst Report?
Active Programs
Tallies all ongoing discovery and development programs using the company’s platform, indicating the pipeline depth and future opportunity for licensing or partner deals. More active programs can mean greater long-term upside, but early-stage programs carry high attrition and uncertain timelines to value realization.Program growth accelerated from late 2024 into 2025, signaling stronger partner adoption of OmniAb’s platforms and creating clearer milestone runway — management’s Q1 milestone surprise and raised revenue guide validate that commercial traction. A broader program base reduces concentration risk and ups future milestone/royalty optionality, but most programs are early-stage so revenue will remain lumpy and royalties distant; converting clinical-stage programs into repeatable milestones while managing cash burn is now the primary execution risk and upside catalyst.
Date | Active Programs |
|---|---|
Jun 30, 2026 | 425.00 |
Mar 31, 2026 | 409.00 |
Dec 31, 2025 | 407.00 |
Sep 30, 2025 | 399.00 |
Jun 30, 2025 | 381.00 |
Mar 31, 2025 | 378.00 |
Dec 31, 2024 | 363.00 |
Sep 30, 2024 | 325.00 |
Jun 30, 2024 | 333.00 |
Mar 31, 2024 | 327.00 |